Association of variants in the SPTLC1 gene with juvenile amyotrophic lateral sclerosis by Johnson, JO et al.
This is a repository copy of Association of variants in the SPTLC1 gene with juvenile 
amyotrophic lateral sclerosis.




Johnson, JO, Chia, R, Miller, DE et al. (295 more authors) (2021) Association of variants in
the SPTLC1 gene with juvenile amyotrophic lateral sclerosis. JAMA Neurology, 78 (10). 





This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Association of Variants in the SPTLC1Gene
With Juvenile Amyotrophic Lateral Sclerosis
Janel O. Johnson, PhD; Ruth Chia, PhD; Danny E. Miller, MD, PhD; Rachel Li, MD; Ravindran Kumaran, PhD; Yevgeniya Abramzon, BSc;
Nada Alahmady, PhD; Alan E. Renton, PhD; Simon D. Topp, PhD; J. Raphael Gibbs, PhD; Mark R. Cookson, PhD; Marya S. Sabir, BSc;
Clifton L. Dalgard, PhD; Claire Troakes, PhD; Ashley R. Jones, PhD; Aleksey Shatunov, PhD; Alfredo Iacoangeli, PhD; Ahmad Al Khleifat, PhD;
Nicola Ticozzi, MD, PhD; Vincenzo Silani, MD; Cinzia Gellera, PhD; Ian P. Blair, PhD; Carol Dobson-Stone, PhD; John B. Kwok, PhD;
Emily S. Bonkowski, ScM; Robin Palvadeau, MSc; Pentti J. Tienari, MD; Karen E. Morrison, MD; Pamela J. Shaw, MD; Ammar Al-Chalabi, PhD;
Robert H. Brown Jr, MD, PhD; Andrea Calvo, PhD; Gabriele Mora, PhD; Hind Al-Saif, MD; Marc Gotkine, MBBS; Fawn Leigh, MD;
Irene J. Chang, MD; Seth J. Perlman, MD; Ian Glass, MB ChB, MD; Anna I. Scott, PhD; Christopher E. Shaw, MD; A. Nazli Basak, PhD;
John E. Landers, PhD; Adriano Chiò, PhD; Thomas O. Crawford, PhD; Bradley N. Smith, PhD; Bryan J. Traynor, MD, PhD;
and the FALS Sequencing Consortium; American Genome Center; International ALS Genomics Consortium; and ITALSGENConsortium
IMPORTANCE Juvenile amyotrophic lateral sclerosis (ALS) is a rare form of ALS characterized
by age of symptom onset less than 25 years and a variable presentation.
OBJECTIVE To identify the genetic variants associated with juvenile ALS.
DESIGN, SETTING, AND PARTICIPANTS In this multicenter family-based genetic study, trio
whole-exome sequencing was performed to identify the disease-associated gene in a case
series of unrelated patients diagnosed with juvenile ALS and severe growth retardation.
The patients and their family members were enrolled at academic hospitals and
a government research facility betweenMarch 1, 2016, andMarch 13, 2020, and were
observed until October 1, 2020.Whole-exome sequencing was also performed in a series
of patients with juvenile ALS. A total of 66 patients with juvenile ALS and 6258 adult patients
with ALS participated in the study. Patients were selected for the study based on their
diagnosis, and all eligible participants were enrolled in the study. None of the participants
had a family history of neurological disorders, suggesting de novo variants as the underlying
genetic mechanism.
MAIN OUTCOMES ANDMEASURES De novo variants present only in the index case and not
in unaffected family members.
RESULTS Trio whole-exome sequencing was performed in 3 patients diagnosed with juvenile
ALS and their parents. An additional 63 patients with juvenile ALS and 6258 adult patients
with ALS were subsequently screened for variants in the SPTLC1 gene. De novo variants in
SPTLC1 (p.Ala20Ser in 2 patients and p.Ser331Tyr in 1 patient) were identified in 3 unrelated
patients diagnosed with juvenile ALS and failure to thrive. A fourth variant (p.Leu39del) was
identified in a patient with juvenile ALS where parental DNAwas unavailable. Variants in this
gene have been previously shown to be associated with autosomal-dominant hereditary
sensory autonomic neuropathy, type 1A, by disrupting an essential enzyme complex in the
sphingolipid synthesis pathway.
CONCLUSIONS AND RELEVANCE These data broaden the phenotype associated with SPTLC1
and suggest that patients presenting with juvenile ALS should be screened for variants in
this gene.
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A
myotrophic lateral sclerosis (ALS) is a relatively com-
mon neurological disorder characterized by progres-
sive paralysis and death from respiratory failure.
The vast majority of cases occur in individuals older than
40 years.1 In contrast, juvenile ALS (defined as an age of on-
set less than 25 years) is a rare formofmotor neurondisease.2
These early-onset cases are characterized by slow progres-
sion and a variable phenotype that often makes accurate
diagnosis challenging.2
Considerable progress has been made in unravelling the
genetic architecture underlying ALS, butmuch remains to be
understood about this condition.3 Juvenile ALS is thought to
bemore frequentlygenetic inorigin thantheadult-onset forms,
and the genetic analysis of these young-onset cases offers
an opportunity to identify disease-causing genes.2 By exten-
sion, any gene underlying juvenile ALSmay also play a role in
adult-onset ALS.
De novo genetic variants may underlie at least a portion
ofALS cases. Suchvariantswouldnot bedetectedbygenome-
wide association studies owing to their recent occurrence and
corresponding low frequencywithin the community. Sponta-
neously occurring variants are a well-known cause of neuro-
logical conditions, such as neurofibromatosis type 1 and
Duchenne muscular dystrophy.4,5 Indeed, de novo variants
of the familial ALS genes FUS, SOD1, and VCP have been de-
scribed in sporadic ALS cases.6,7 Such variants aremore likely
to present with early-onset disorders because of their impact
on fitness.8
Here, we performed whole-exome sequencing of 3 pa-
tients diagnosed with juvenile ALS and their unaffected par-
ents to identify thevariantsassociatedwith theirdisease.None
of these patients had a family history of neuromuscular dis-
orders, suggesting de novo variations as the underlying ge-
netic mechanism. After identifying variants in serine palmi-
toyltransferase, long-chain base subunit 1 (SPTLC1; OMIM,
605712) in all 3 cases, we also screened patientswith juvenile
ALS from Turkey for SPTLC1 variants and identified a fourth
patient carrying an SPTLC1 variant.
Methods
Patients
Four unrelated patients with neuromuscular symptoms con-
sistent with juvenile ALS participated in the study between
March2016andJanuary2021.TheTable summarizes theclini-
cal features of the 4 patients. Detailed descriptions of each
patient and their recruitment are available in the eMethods in
the Supplement. All participants provided written informed
consent for genetic analysis according to the Declaration of
Helsinki, and the Institutional Review Board of the National
Institutes ofHealth approved the study.Members of theFALS
Sequencing Consortium, American Genome Center, Interna-
tional ALS Genomics Consortium, and ITALSGEN Consor-
tium can be found in the eAppendix of the Supplement.
Patient 1 presented with gradually progressive spastic
diplegia and growth retardation beginning at age 5 years. By
age 20 years, she had quadriplegia withmarkedmuscle atro-
phy anddiminishedweight, brisk lower limb reflexes, tongue
fasciculations and weakness, dysarthria, mild cognitive dys-
function, and respiratory failure requiring tracheostomy
and ventilation. Repeated neurophysiological testing did not
showevidenceof sensory or autonomicdysfunction. Shewas




sive generalized limb and bulbar weakness. She had a long-
standing history of progressive weight loss of unknown
cause, and her school performance began to decline in her
mid-teens. Her neurological examination at presentation re-
vealed a bodymass index less than the first percentile, exag-
gerated lumbar lordosis, tongue fasciculations and wasting,
generalizedmuscle atrophy andweakness, brisk asymmetric
ankle reflexes, a positive Gower sign, and normal sensation
(Figure 1A and B). Neurophysiological testing revealed active
and chronic denervation without evidence of sensory neu-
ropathy. Decreased sustained attention and impaired execu-
tive functioning were evident in neuropsychological evalua-
tion.Shewasdiagnosedwith juvenileALSbasedonthe revised
El Escorial criteria.9
Patient 3 was an 11-year-old African American girl with
a history of failure to gain weight and toe walking since age
4 years. She presented at age 10 years with a deteriorating
gait, hand weakness, right foot paresthesia, dysphagia, and
increased sweating. Examination revealed marked atrophy,
postural tachycardia, bilateral cataracts, awastedand fascicu-
lating tongue with an exaggerated jaw jerk, generalized fas-
ciculations and weakness associated with hyperreflexia, and
decreased pinprick sensation in a glove-and-stocking distri-
bution (Figure 1C and D). The patient walked abnormally ow-
ing to weakness and bilateral foot drop, and she had a posi-
tive Gower sign. Neurophysiological examination showed
sensorimotor axonal neuropathy aswell as polyphasic poten-
tials on electromyography. She was diagnosed with juvenile
ALS-Plus syndrome owing to her prominent motor symp-
toms andmodest sensory-autonomic involvement. Thepedi-
grees of patients 1, 2, and 3 are shown in Figure 2A to C.
Patient 4 was a 34-year-old Turkish woman with a his-
tory of arm and leg weakness and atrophy since age 15 years.
There was no family history of neuromuscular disease, and
Key Points
Question What genetic variants are associated with juvenile
amyotrophic lateral sclerosis (ALS)?
Findings In this family-based genetic study, exome sequencing
was performed in 3 patients diagnosed with juvenile ALS and
failure to thrive; this identified de novo variants in SPTLC1
(p.Ala20Ser in 2 patients and p.Ser331Tyr in 1 patient). Variants
in SPTLC1 are a known cause of hereditary sensory and autonomic
neuropathy, type 1A, and these data extend the phenotype
associated with this gene.
Meaning De novo variants in the SPTLC1 gene are associated with
juvenile ALS, a fatal neurological disorder.
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none of her 5 siblings had symptoms (Figure 2D). She was di-
agnosed with juvenile ALS, and she has been taking riluzole
sinceage 15years.Her symptomswere slowlyprogressive, and
therewerenouppermotorneuron signsonexamination.Dur-
ing her last review at age 34 years, she used a wheelchair,
although she could walk short distances with assistance. She
had no dysphagia and did not require oxygen supplementa-
tion, and her weight was normal. Neurophysiological exami-
nationat that time revealeddenervationactivity in allmuscles
and no evidence of multifocal motor neuropathy.
For variant screening of SPTLC1 in adult-onset ALS, we
used 6258 DNA samples obtained from individuals diag-
nosed with adult-onset ALS (eTable 1 in the Supplement).
Control data consisted of 5710 neurologically healthy US
individuals who had undergone next-generation sequencing
at the Laboratory of Neurogenetics of the National Institute
on Aging, National Institutes of Health, Bethesda, Maryland,
or the Alzheimer Disease Sequencing Project.
Next-Generation Sequencing in Juvenile ALS
Whole-exome sequencing was performed using 100 base-
pair, paired-end sequencing on an Illumina sequencer (eg,
HiSeq 2000) according to the manufacturer’s protocol. DNA
from patient 1 and her family was sequenced in the Labora-
tory of Neurogenetics using TruSeq library preparation ver-
sion 1.0. DNA from patients 2 and 3 and their families was
sequenced at GeneDx using IDT xGen Exome Research Panel
version 1.0.10
Data were analyzed to identify de novo variants present
in the affected child and not present in either parent. As the
variants underlying a rare disease, such as ALS, are unlikely
to be present in the general population, variants present in
the Genome Aggregation Database (gnomAD; version 2.1) or
the Kaviar Genomic Variant database (September 23, 2015,
version) were excluded. Synonymous, intronic, and inter-
genic changes were excluded (ANNOVAR; August 11, 2016,
version). Paternity andmaternitywere confirmedusing iden-
tity-by-descent analysis, and exome data were reviewed to
identify variants in known ALS genes.
SPTLC1 Sequencing in Adult-Onset ALS
DNA from 6258 patients with adult-onset ALS were se-
quenced to identify variants in the SPTLC1 gene (whole-
exome sequencing, 3748 cases11,12; whole-genome sequenc-
ing, 1860 cases; Sanger sequencing, 650 cases) (eTable 2 in
the Supplement). Variants in SPTLC1 were considered to be
deleterious if they(1)werenotpresent in the4647controls from
the Alzheimer Disease Sequencing Project; (2) had a fre-
quency less than 3.3 × 10−5 in human variant databases, in-
cluding the 51 592European and8949Finnishnonneurologi-
cal individuals in gnomAD and the 77 301 samples in Kaviar
database3; and (3) were designated as damaging according to
4 of 5 prediction algorithms,13 were identified as stop gain or
frameshift, or were identified as splice-site variants with a
dbscSNVscorehigher than0.6.Geneburden testingofSPTLC1
was performed using publicly available control data (gno-
Table. Clinical Features of Patients DiagnosedWith Juvenile Amyotrophic Lateral Sclerosis
and Carrying Variants in SPTLC1
Clinical feature Patient 1 Patient 2 Patient 3 Patient 4
Gene change p.Ala20Ser p.Ala20Sera p.Ser331Tyr p.Leu39del
Age at onset 5 y <10 y 4 y 15 y
Age at evaluation 20 y 10s 11 y 34 y







Back deformities Severe scoliosis Lordosis Normal posture NA
Foot deformities Pes cavus NA Pes cavus/varus NA
Walking Nonambulatory Steppage Steppage Abnormal
Atrophy Global, contractures Global Global Global

















Jaw jerk Present NA Present NA

























Abbreviations: BMI, bodymass index;
NA, not applicable.
a Variant was detected in 1 of 49 and
0 of 149 next-generation
sequencing reads from the father’s
saliva-derived and buccal-derived
DNA, respectively.
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mAD and Kaviar databases) as implemented in the Test Rare
Variants With Public Data (TRAPD) software package version
1.0.14The statistical significance thresholdwas set at a 1-tailed
Pvalue less than .05 for single-geneanalysis and2.5 × 10−6 for
genome-wide significance (.05/20000 genes).
Cellular Mitochondrial Assays
Variants were introduced into a plasmid containing the
human SPTLC1 open reading frame (Origene) using the
QuikChange II XL kit (Agilent), followed by subcloning into
pLenti-C-Myc-DDK-P2A-Puro lentiviral plasmid (Origene).
Lentiviruses were produced with third-generation packaging
plasmids (pMDLg/pRRE and pRSV-Rev; Addgene) and enve-
lopeplasmid (pMD2.G;Addgene).15HEK293FTcellswere trans-
fectedwithwild-typeorvariant lentivirus transferplasmid,and
transduced cells stably expressing SPTLC1 were selected by
extended growth in 0.5-μg/mL puromycin (Thermo Fisher
Scientific). For the serine rescue experiment, a final concen-
trationof100-mML-serinewasaddedtothemediafor48hours.
Mitochondria were imaged with MitoTracker Red CMXRos
(ThermoFisher Scientific) using aCellInsight imager (Thermo
Fisher Scientific). A minimum of 6 wells were quantified for
each condition, and all assays were performed at least twice.
Unpaired t test with Welch correction or analysis of variance
were used to calculate statistical significance.
SphingolipidMeasurements
Plasma sphingolipid and glucosylceramide measurements
were performed at the Biomedical Genetics Clinical Labora-
tory, Seattle Children’s Hospital, Seattle, Washington, using
high-performance liquid chromatography and tandem mass
spectrometry.
Results
Identification of De Novo Variants in SPTLC1
AssociatedWith Juvenile ALS
We performed whole-exome sequencing in 3 unrelated pa-
tients who had been diagnosed with juvenile ALS and their
healthy parents (Figure 1; Figure 2A to C; Table). The analysis
of their genetic data identifieddenovovariants in the SPTLC1
gene in each of the 3 patients that were absent in their par-
ents (Figure 2E). Patients 1 and 2 carried the same heterozy-
gous p.Ala20Ser variant in SPTLC1 caused by variation
in adjacent nucleotides (chr9:94874844C>A and chr9:
Figure 1. Clinical Features of Patients DiagnosedWith Juvenile Amyotrophic Lateral Sclerosis
Tongue wasting in patient 2A Scapular winging in patient 2B
Tongue wasting in patient 3C Leg muscle atrophy in patient 3D
A and B, Tongue wasting and scapular
winging in patient 2 carrying the
p.Ala20Ser SPTLC1 variant.
C and D, Tongue wasting andmuscle
atrophy of the lower limbs in patient
3 carrying the p.Ser331Tyr SPTLC1
variant. Note the hammertoe
deformities of both feet.
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94874843G>T; human genome build hg19). Patient 3 carried
ap.Ser331Tyr (chr9:94809543G>T) heterozygous variation in
SPTLC1. Screening of the SPTLC1 gene in a cohort of 63 pa-
tients with juvenile ALS from Turkey who had undergone
whole-exome sequencing identified a p.Leu39del (chr9:
94874785_94874787del) heterozygous variant in patient 4
(Figure 2D). Parental DNAwasnot available,making it impos-
sible to determine if the deletion had occurred spontane-
ously. These SPTLC1 variants were not present in controls
or online databases of human variants (142489 individuals).
Thep.Ser331Tyrandp.Leu39delaminoacidchangeshavebeen
previously implicated in neurological disease.16
Serine and the Damaging Effects
of the p.Ala20Ser Variant in Vitro
Variants in SPTLC1 are a known cause of autosomal-dominant
hereditarysensoryandautonomicneuropathy, type1A(HSAN1;
OMIM, 162400).17,18 The protein encoded by SPTLC1 is an
essential subunit of serine palmitoyltransferase (SPT), the en-
zymethatcatalyzesthefirstandrate-limitingstepinthedenovo
synthesis of sphingolipids.19Acharacteristic featureofSPTLC1
variants associated with HSAN1 is a shift in substrate specific-
ity of SPT to L-alanine and L-glycine, leading to the formation
of an atypical class of deoxysphingolipids.20These neurotoxic
metabolites accumulate within cells as they cannot be con-
verted to complex sphingolipidsnordegradedby the catabolic
pathway.20
Based on this information, we used a photometric assay
ofSPTenzymeactivity toexplore theassociationof thedenovo
variants with protein function.We found that the p.Ala20Ser
variant SPTLC1 complex had an altered L-alanine and glycine
preferenceover thecanonicalL-serinecomparedwith thewild-
type SPTLC1 complex (Figure 3A; eFigure 1 in the Supple-
ment). Differences were also observed using cell-based as-
says based on established HSAN1-mitochondrial phenotypes
(Figure 3B and C; eFigure 1 in the Supplement).21 Mitochon-
drial size and intensity were defective to the same degree in
cells expressing p.Ala20Ser and p.Cys133Trp. These defects
were reversed to the wild-type phenotype on serine supple-
mentation in the culture (Figure 3B and C; eFigure 1 in the
Supplement).
SPTLC1Variants in PatientsWith Adult-Onset ALS
Havingestablished that variants inSPTLC1are associatedwith
juvenile ALS, we explored the role of variation in this gene in
the pathogenesis of adult-onset ALS by evaluating the occur-
renceofSPTLC1variants ina seriesof6258patientswithadult-
onset ALS. This screening identified 20 novel SPTLC1 vari-
ants in 23 patientswithALS (0.4%) thatwere rare or absent in
healthy controls andwere predicted to be damaging (eTable 3
and eFigures 2 and 3 in the Supplement). The typical clinical
featuresofALSwereobservedamongthesepatientswithadult-
onset disease, and none of the patients reported sensory or
autonomic involvement (eTable 4 in the Supplement). The
intensity andnumber ofmotor neurons stainingwith SPTLC1
were diminished in autopsy tissue obtained from a patient
with ALS carrying a p.Arg445Gln variant in SPTLC1 (eFig-
ure 4 in the Supplement). Gene burden testing was not sig-
Figure 2. De Novo Variants of SPTLC1 in Patients DiagnosedWith Juvenile Amyotrophic Lateral Sclerosis (ALS)















Distribution of SPTLC1 variants detected in patients with juvenile ALSE


































94 793 427 94 877 690chromosome 9q22.31
Ser331 Tyr 
AAT superfamily (fold type 1)
Leu39delAla20Ser
A-D, Pedigrees of 4 patients diagnosed with juvenile ALS. The variant alleles
in SPTLC1 are indicated by vt, and wild-type alleles are indicated by wt. The
arrowheads indicate the probands. E, Distribution of SPTLC1 variants detected
in patients diagnosed with juvenile ALS. Variants identified in the 3 patients
with juvenile ALS are noted in red, and variants previously described to cause
hereditary sensory and autonomic neuropathy, type 1A, are shown in green.
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nificant for SPTLC1 variants as a cause of adult-onset ALS
(87variants inpopulation samples; uncorrected 1-sidedFisher
test P value using TRAPD software package = 1.9 × 10−4; not
significant after correction for multiple testing of 20 000
genes).
Discussion
Weprovide genetic, biochemical, and cellular data that varia-
tions in SPTLC1 are associated with juvenile ALS. First, we
found 3 unrelated patients diagnosed with juvenile ALS who
carried de novo variants in SPTLC1 and identified a fourth pa-
tient with juvenile ALS carrying another SPTLC1 variant for
whom inheritance could not be determined. These variants
were not present in our in-house control data set or in online
databases of human variants, indicating they were rare vari-
ants in diverse populations. Two of the patients carried the
same alanine to serine amino acid shift at position 20 of
the protein, which arose from different nucleotide changes.
Second, cell-based assays of SPT activity confirmed that the
p.Ala20Ser variation altered the encoded enzyme’s function,
leading to increased aberrant utilization of alanine and gly-
cine as substrates. This biochemical pattern was consistent
with a mechanism reported in patients with HSAN1 caused
by SPTLC1 variants.20 Third, we used immunohistochemis-
try todemonstrate thatSPTLC1 is abundantlyexpressedwithin
the motor neurons of healthy spinal cord tissue.
Though labeledasHSAN1, thephenotypesassociatedwith
variants in SPTLC1 are varied, with patientsmanifesting vari-
ous combinationsof sensory loss, autonomicdysfunction, and
motor weakness.22 Indeed, there is a previous report of a de
novop.Ser331Tyr variant inSPTLC1 in a youngFrenchgirl pre-
sentingwithasimilarphenotype to thepatients in thisarticle.16
Herclinical picture consistedof severegrowth restriction, cog-
nitive impairment, amyotrophy, hyperreflexia, vocal cordpa-
ralysis, and respiratory failure, although this patient was not
diagnosed as having juvenile ALS. More recently, retinal dis-
easehas been reported inpatients carryingSPTLC1variants.23
This clinical heterogeneity has been linked to thediffering ef-
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A, The SPTLC1 enzyme complex activity was determined using a photometric
assay measuring the release of free coenzyme A (coA) from the condensation
reaction between palmitoyl-CoA and L-serine, L-alanine, and L-glycine. The
variant p.Ala20Ser and p.Cys133Trp SPTLC1 complex had increased preference
for L-alanine and L-glycine over L-serine compared with the wild-type (WT)
SPTLC1 complex. B and C, Mitochondria in HEK293 cells expressingWT,
p.Ala20Ser, and p.Cys133Trp were assessed using MitoTracker on a high-content
imager. Mitochondrial intensity andmitochondria size were smaller in cells
expressing variant protein under standard culture conditions. Supplementation
of 100mM L-serine in the culture media for 48 hours rescued themitochondrial
abnormalities in the p.Ala20Ser and p.Cys133Trp lines.
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fectsofeachvariantonSPTLC1enzyme-substratepreference,20
and we observed similar differences in substrate utilization
across the variants thatwehad studied at the enzymatic level
(Figure3A).Alternatively, thephenotypesassociatedwithvari-
ants in HSAN1 may represent a continuum between sensory
neuropathy and ALS. Future postmortem studies that deter-
mine the central nervous system pathology (eg, TAR DNA-
bindingprotein43, tau, β-amyloiddeposition) underlying the
motor neuron deficits and the cognitive impairment may re-
solve the nature of this overlap with other neurodegenera-
tive diseases.
Perturbed sphingolipid metabolism underlies many
neurological disorders, such as Niemann-Pick disease and
Gaucher disease,24 andmay play a role in the pathogenesis of
Alzheimer disease.25 Sphingolipid metabolism has also been
implicated in motor neuron degeneration. For example, pa-
tients with partial deficiency of hexosaminidase A enzyme
activity (also known as GM2 gangliosidosis, a form of sphin-
golipidosis) may have clinical manifestations mimicking
ALS.26 The accumulation of ceramides and cholesterol esters
also occurs within the spinal cords of patients with ALS and
an SOD1 transgenic mouse model of ALS.27
Owing to the poor prognosis observed among patients
with juvenile ALS and work published by other groups,20,28
patient 2 was commenced on high-dose (10 g per day) oral
serine supplementation on a compassionate basis. Her body
weight increased during this off-label treatment, which was
the first time she had gained weight in several years. The
patient’s ceramide levels were within normal range and
trending downwards, indicating that ceramide toxic effects,
a theoretical possibility with serine treatment, were not pre-
sent (eFigure 5 and eTable 5 in the Supplement). We did not
observe evidence of neurological improvement, although
prolonged therapy would be required to detect such an
effect.29
Serine is a nonessential amino acid that is available as a
low-cost nutritional supplement. A 10% serine-enriched diet
was associatedwith a reduction inneurotoxic deoxysphingo-
lipid plasma levels both in transgenic mice expressing the
p.Cys133Trp SPTLC1 variant and in human patients diag-
nosedwithHSAN1.28 Furthermore, a safety trial involving 20
patients with adult-onset ALS demonstrated that high doses
of oral serine arewell tolerated and that this polar amino acid
is actively transported across the blood-brain barrier.30Nutri-
tional supplementation has proven to be remarkably effec-
tive in other forms of ALS.31 Despite these supportive data,
future clinical trials are needed to determine the effective-
ness and safety profile of serine supplementation in patients
with juvenile ALS owing to SPTLC1 variants.
Limitations
Our studyhad limitations.DNAwasnotavailable fromthepar-
ents of patient 4, so it was not possible to determinewhether
ornot thevariationarosespontaneously.Nevertheless, the lack
of a familyhistory supports thepossibility that thisvariantwas
de novo in origin; there is only a 3.1% chance that none of her
5 siblingswould have inherited an autosomal-dominant vari-
ant from a transmitting parent. Our evidence also demon-
strates thatvariants inSPTLC1arenotacommoncauseofadult-
onset ALS. Overall, our data imply that the genetic causes of
juvenile ALS and adult-onset ALS are distinct.
Conclusions
Inconclusion,ourdatabroaden thephenotypeassociatedwith
variants inSPTLC1 to include juvenileALSand implicate sphin-
golipid metabolism as a pathway in motor neuron disease.
Our findings are relevant in light of the fact that nutritional
supplementation with serine has been postulated to amelio-
rate the toxic effect of abnormal sphingolipid metabolites if
instituted at an early stage in the disease.28 In such cases,
abnormal plasma metabolites could be used as a marker of
target engagement.32 This provides an early opportunity for
future clinical trials to test the precision medicine approach
in an otherwise fatal neurodegenerative disease.
ARTICLE INFORMATION
Accepted for Publication:May 27, 2021.
Published Online: August 30, 2021.
doi:10.1001/jamaneurol.2021.2598
Open Access: This is an open access article
distributed under the terms of the CC-BY License.
© 2021 Johnson JO et al. JAMA Neurology.
Author Affiliations:Neuromuscular Diseases
Research Section, Laboratory of Neurogenetics,
National Institute on Aging, National Institutes of
Health, Bethesda, Maryland (Johnson, Chia,
Abramzon, Renton, Traynor); Division of Medical
Genetics, Department of Medicine, University of
Washington, Seattle (Miller, Chang, Glass);
Department of Pediatrics, Division of Genetic
Medicine, Seattle Children’s Hospital, University of
Washington, Seattle (Miller, Bonkowski, Glass);
Department of Pediatrics, Children’s Hospital of
Richmond at VCU, Richmond, Virginia (Li); Cell
Biology and Gene Expression Section, Laboratory of
Neurogenetics, National Institute on Aging,
National Institutes of Health, Bethesda, Maryland
(Kumaran); Reta Lila Weston Institute, UCL Queen
Square Institute of Neurology, University College
London, London, United Kingdom (Abramzon,
Cookson, Traynor); MauriceWohl Clinical
Neuroscience Institute, Institute of Psychiatry,
Psychology and Neuroscience, King’s College
London, London, United Kingdom (Alahmady,
Topp, Troakes, Jones, Shatunov, Iacoangeli,
Al Khleifat, Al-Chalabi, C. E. Shaw, Smith);
Department of Biology, Imam Abdulrahman bin
Faisal University, Dammam, Saudi Arabia
(Alahmady); Nash Family Department of
Neuroscience, Icahn School of Medicine at Mount
Sinai, New York, New York (Renton); Ronald M.
Loeb Center for Alzheimer’s Disease, Icahn School
of Medicine at Mount Sinai, New York, New York
(Renton); Department of Genetics and Genomic
Sciences, Icahn School of Medicine at Mount Sinai,
New York, New York (Renton); UK Dementia
Research Institute at King’s College London,
London, United Kingdom (Topp, C. E. Shaw);
Computational Biology Group, Laboratory of
Neurogenetics, National Institute on Aging,
National Institutes of Health, Bethesda, Maryland
(Gibbs); Neurodegenerative Diseases Research
Unit, Laboratory of Neurogenetics, National
Institute of Neurological Disorders and Stroke,
National Institutes of Health, Bethesda, Maryland
(Sabir); Department of Anatomy, Physiology &
Genetics, Uniformed Services University of the
Health Sciences, Bethesda, Maryland (Dalgard);
The American Genome Center, Collaborative Health
Initiative Research Program, Uniformed Services
University of the Health Sciences, Bethesda,
Maryland (Dalgard); Istituto Auxologico Italiano,
IRCCS, Department of Neurology–Stroke Unit and
Laboratory of Neuroscience, Milan, Italy (Ticozzi,
Silani); Department of Pathophysiology and
Transplantation, “Dino Ferrari” Center, Università
degli Studi di Milano, Milan, Italy (Ticozzi, Silani);
Unit of Genetics of Neurodegenerative and
Metabolic Diseases, Fondazione IRCCS Istituto
Neurologico ‘Carlo Besta,’ Milan, Italy (Gellera);
Centre for Motor Neuron Disease Research,
Department of Biomedical Sciences, Faculty of
Medicine and Health Sciences, Macquarie
Research Original Investigation Association of Variants in the SPTLC1 GeneWith Juvenile Amyotrophic Lateral Sclerosis
1242 JAMANeurology October 2021 Volume 78, Number 10 (Reprinted) jamaneurology.com
Downloaded From: https://jamanetwork.com/ on 11/29/2021
University, Sydney, Australia (Blair); The University
of Sydney, Brain andMind Centre and School of
Medical Sciences, Faculty of Medicine and Health,
Camperdown, Australia (Dobson-Stone, Kwok);
School of Medical Sciences, University of New
SouthWales, Kensington, Australia (Dobson-Stone,
Kwok); Suna and Inan Kırac Foundation,
Neurodegeneration Research Laboratory, KUTTAM,
School of Medicine, Koc University, Istanbul, Turkey
(Palvadeau, Basak); Department of Neurology,
Helsinki University Hospital and Translational
Immunology Programme, Biomedicum, University
of Helsinki, Helsinki, Finland (Tienari); Faculty of
Medicine, Health and Life Sciences, Queen’s
University Belfast, Belfast, United Kingdom
(Morrison); Sheffield Institute for Translational
Neuroscience, Department of Neuroscience,
University of Sheffield, Sheffield, United Kingdom
(P. J. Shaw); Department of Neurology, King’s
College Hospital, London, United Kingdom
(Al-Chalabi); Department of Neurology, University
of Massachusetts Medical School, Worcester
(Brown, Landers); ALS Center, ‘Rita Levi Montalcini’
Department of Neuroscience, University of Turin,
Turin, Italy (Calvo, Chiò); ALS Center, ICS Maugeri,
IRCCS, Milan, Italy (Mora); Department of
Neurology, Children’s Hospital of Richmond at VCU,
Richmond, Virginia (Al-Saif); Department of
Neurology, The Agnes Ginges Center for Human
Neurogenetics, HadassahMedical Organization and
Faculty of Medicine, Hebrew University of
Jerusalem, Jerusalem, Israel (Gotkine); Department
of Neurology, Seattle Children’s Hospital, University
of Washington, Seattle (Leigh, Perlman);
Department of Laboratories, Seattle Children’s
Hospital, Seattle, Washington (Scott); Department
of Laboratory Medicine, University of Washington,
Seattle (Scott); Neurology 1, AOU Città della Salute
e della Scienza, Turin, Italy (Chiò); Department of
Neurology, Johns Hopkins University, Baltimore,
Maryland (Crawford, Traynor); Department of
Pediatrics, Johns Hopkins University, Baltimore,
Maryland (Crawford); National Institute of
Neurological Disorders and Stroke, Bethesda,
Maryland (Traynor).
The FALS Sequencing Consortium, American
GenomeCenter, International ALS Genomics
Consortium, and ITALSGENConsortiumAuthors:
Bradley N. Smith, PhD; Nicola Ticozzi, MD, PhD;
Claudia Fallini, PhD; Athina Soragia Gkazi, PhD;
Simon D. Topp, MSc; Emma L. Scotter, PhD; Kevin P.
Kenna, PhD; Pamela Keagle, BS; Cinzia Tiloca, PhD;
Caroline Vance, PhD; Claire Troakes, PhD; Claudia
Colombrita, PhD; Andrew King, FRCPath; Viviana
Pensato, PhD; Barbara Castellotti, PhD; Frank Baas,
MD, PhD; Anneloor L. M. A. ten Asbroek, PhD;
DianeMcKenna-Yasek, RN; Russell L. McLaughlin,
PhD; Meraida Polak, RN; Seneshaw Asress, MSc;
Jesús Esteban-Pérez, MD; Zorica Stevic, MD, PhD;
Sandra D’Alfonso, PhD; Letizia Mazzini, MD;
Giacomo P. Comi, MD; Roberto Del Bo, PhD; Mauro
Ceroni, MD; Stella Gagliardi, PhD; Giorgia Querin,
MD; Cinzia Bertolin, PhD; Wouter van Rheenen,
MD; Rosa Rademakers, PhD; Marka van Blitterswijk,
MD, PhD; Giuseppe Lauria, MD; Stefano Duga, PhD;
Stefania Corti, MD, PhD; Cristina Cereda, PhD; Lucia
Corrado, PhD; Gianni Sorarù, MD, PhD; Kelly L.
Williams, PhD; Garth A. Nicholson, PhD; Ian P. Blair,
PhD; Claire Leblond-Manry, PhD; Guy A. Rouleau,
MD, PhD; Orla Hardiman, MD; Karen E. Morrison,
MD; Jan H. Veldink, MD, PhD; Leonard H.
van den Berg, MD, PhD; Ammar Al-Chalabi, MD,
PhD; Hardev Pall, MD; Pamela J. Shaw, MD; Martin
R. Turner, MD; Kevin Talbot, MD; Franco Taroni, MD;
Alberto García-Redondo, PhD; ZheyangWu, PhD;
Jonathan D. Glass, MD; Cinzia Gellera, PhD; Antonia
Ratti, PhD; Robert H. Brown Jr, MD, DPhil; Vincenzo
Silani, MD; Christopher E. Shaw, MD; John E.
Landers, PhD; Clifton L. Dalgard, PhD; Adelani
Adeleye, MS; Anthony R. Soltis, PhD; Camille Alba,
MS; Coralie Viollet, PhD; Dagmar Bacikova, MS;
Daniel N. Hupalo, PhD; Gauthaman Sukumar, MS;
Harvey B. Pollard, MD, PhD; Matthew D.Wilkerson,
PhD; Elisa McGrath Martinez, BS; Yevgeniya
Abramzon, BS; Sarah Ahmed, BS; Sampath Arepalli,
MS; Robert H. Baloh, MD; Robert Bowser, PhD;
Christopher B. Brady, PhD; Alexis Brice, MD; James
Broach, PhD; Roy H. Campbell, PhD; William Camu,
MD; Ruth Chia, PhD; John Cooper-Knock, MD;
Jinhui Ding, PhD; Carsten Drepper, PhD; Vivian E.
Drory, MD; Travis L. Dunckley, PhD; John D. Eicher,
PhD; Bryce K. England, BS; Faraz Faghri, BS; Eva
Feldman, MD; Mary Kay Floeter, MD; Pietro Fratta,
MD; Joshua T. Geiger, MD; Glenn Gerhard, MD;
J. Raphael Gibbs, PhD; Summer B. Gibson, MD;
Jonathan D. Glass, MD; John Hardy, PhD; Matthew
B. Harms, MD; Terry D. Heiman-Patterson, MD;
Dena G. Hernandez, PhD; Lilja Jansson; Janine
Kirby, PhD; Neil W. Kowall, MD; Hannu Laaksovirta,
MD; Natalie Landeck, PhD; Francesco Landi, MD;
Isabelle Le Ber, MD, PhD; Serge Lumbroso, MD;
Daniel J. L. MacGowan, MD; Nicholas J. Maragakis,
MD; Gabriele Mora, MD; Kevin Mouzat, MD; Natalie
A. Murphy, BS; Liisa Myllykangas, MD, PhD; Mike A.
Nalls, PhD; RichardW. Orrell, MD; LyleW. Ostrow,
MD, PhD; Roger Pamphlett, MD; Stuart
Pickering-Brown, PhD; Erik P. Pioro, MD; Olga
Pletnikova, MD; Hannah A. Pliner, PhD; StefanM.
Pulst, MD; JohnM. Ravits, MD; Alan E. Renton,
PhD; Alberto Rivera, BS; Wim Robberecht, MD;
Ekaterina Rogaeva, PhD; Sara Rollinson, PhD;
Jeffrey D. Rothstein, MD, PhD; SonjaW. Scholz, MD,
PhD; Michael Sendtner, MD; Pamela J. Shaw, MD;
Katie C. Sidle, MD; Zachary Simmons, MD; Andrew
B. Singleton, PhD; Nathan Smith, PhD; David J.
Stone, PhD; Pentti J. Tienari, MD, PhD; Juan C.
Troncoso, MD; Miko Valori, PhD; Philip Van Damme,
MD; ViviannaM. Van Deerlin, MD, PhD; Ludo
Van Den Bosch, PhD; Lorne Zinman, MD; John E.
Landers, PhD; Adriano Chiò, MD; Bryan J. Traynor,
MD, PhD; Stefania M. Angelocola, MD; Francesco P.
Ausiello, MD; Marco Barberis, BSc; Ilaria Bartolomei,
MD; Stefania Battistini, MD, PhD; Enrica Bersano,
MD; Giulia Bisogni, MD; Giuseppe Borghero, MD;
Maura Brunetti, BSc; Corrado Cabona, MD; Andrea
Calvo, MD, PhD; Fabrizio Canale, MD; Antonio
Canosa, MD, PhD; Teresa A. Cantisani, MD;
Margherita Capasso, MD; Claudia Caponnetto, MD;
Patrizio Cardinali, MD; Paola Carrera, PhD; Federico
Casale, PhD; Adriano Chiò, MD; Tiziana Colletti, MD;
Francesca L. Conforti, MD; Amelia Conte, MD; Elisa
Conti, MD; Massimo Corbo, MD; Stefania Cuccu,
PsyD; Eleonora Dalla Bella, MD; Eustachio D’Errico,
MD; Giovanni DeMarco, PhD; Raffaele Dubbioso,
MD; Carlo Ferrarese, MD; Pilar M. Ferraro, PhD;
Massimo Filippi, MD, PhD; Nicola Fini, MD; Gianluca
Floris, MD; Giuseppe Fuda, BSc; Salvatore Gallone,
MD; Giulia Gianferrari, MD; Fabio Giannini, MD,
PhD; Maurizio Grassano, MD; Lucia Greco, PsyD;
Barbara Iazzolino, PsyD; Alessandro Introna, MD;
Vincenzo La Bella, MD, PhD; Serena Lattante, PhD;
Giuseppe Lauria, MD; Rocco Liguori, MD, PhD;
Giancarlo Logroscino, MD, PhD; Francesco O.
Logullo, MD; Christian Lunetta, MD; Paola Mandich,
MD; Jessica Mandrioli, MD; Umberto Manera, MD;
Fiore Manganelli, MD; GiuseppeMarangi, MD;
Kalliopi Marinou, MD; Maria GiovannaMarrosu, MD;
Ilaria Martinelli, MD; Sonia Messina, MD, PhD;
Cristina Moglia, MD, PhD; Gabriele Mora, MD;
LorenaMosca, PhD; Maria R. Murru, MD; Paola
Origone, PhD; Carla Passaniti, MD; Cristina Petrelli,
MD; Antonio Petrucci, MD; Susanna Pozzi, PsyD;
Maura Pugliatti, MD, PhD; Angelo Quattrini, MD,
PhD; Claudia Ricci, MD; Giulia Riolo, PhD; Nilo Riva,
MD, PhD; Massimo Russo, MD; Mario Sabatelli, MD;
Paolina Salamone, PhD; Marco Salivetto, PhD;
Fabrizio Salvi, MD; Marialuisa Santarelli, MD; Luca
Sbaiz, BSc; Riccardo Sideri, MD; Isabella Simone,
MD; Cecilia Simonini, MD; Rossella Spataro, MD;
Raffaella Tanel, MD; Gioacchino Tedeschi, MD;
Anna Ticca, MD; Antonella Torriello, MD; Stefania
Tranquilli, MD; Lucio Tremolizzo, MD; Francesca
Trojsi, MD; Rosario Vasta, MD; Veria Vacchiano, MD;
Giuseppe Vita, MD, PhD; Paolo Volanti, MD;
Marcella Zollino, MD; Elisabetta Zucchi, MD.
Affiliations of The FALS Sequencing Consortium,
American GenomeCenter, International ALS
Genomics Consortium, and ITALSGEN
ConsortiumAuthors: Centre for
Neurodegeneration Research, King’s College
London, Department of Clinical Neuroscience,
Institute of Psychiatry, London, United Kingdom
(B. N. Smith, Gkazi, Topp, King); Department of
Neurology and Laboratory of Neuroscience, IRCCS
Istituto Auxologico Italiano, Milan, Italy (Ticozzi,
Ratti, Silani); Department of Pathophysiology and
Transplantation, “Dino Ferrari” Center, Università
degli Studi di Milano, Milan, Italy (Ticozzi, Silani);
Department of Neurology, University of
Massachusetts Medical School, Worcester (Fallini,
Kenna, Keagle, McKenna-Yasek, Brown Jr, John E.
Landers); UK Dementia Research Institute at King’s
College London, London, United Kingdom (Topp,
C. E. Shaw); Centre for Brain Research, University of
Auckland, Auckland, New Zealand (Scotter);
Department of Neurology, IRCCS Istituto
Auxologico Italiano, Milan, Italy (Tiloca,
Colombrita); MauriceWohl Clinical Neuroscience
Institute, Department of Basic and Clinical
Neuroscience, King’s College London, London,
United Kingdom (Vance, Troakes, Al-Chalabi,
C. E. Shaw); Unit of Medical Genetics and
Neurogenetics, Fondazione IRCCS Istituto
Neurologico ‘Carlo Besta,’ Milan, Italy (Pensato,
Castellotti, Taroni, Gellera); Clinical Genetics, Leiden
University Medical Center, Leiden, the Netherlands
(Baas); Department of Neurogenetics and
Neurology, Academic Medical Centre, Amsterdam,
the Netherlands (ten Asbroek); Population Genetics
Laboratory, Smurfit Institute of Genetics, Trinity
College Dublin, Dublin, Republic of Ireland
(McLaughlin); Department of Neurology, Emory
University, Atlanta, Georgia (Polak, Asress,
Jonathan D. Glass); Unidad de ELA, Instituto de
Investigación Hospital 12 de Octubre deMadrid,
SERMAS, and Centro de Investigación Biomédica en
Red de Enfermedades Raras (CIBERER U-723),
Madrid, Spain (Esteban-Pérez, García-Redondo);
Neurology Clinic, Clinical Center of Serbia School of
Medicine, University of Belgrade, Belgrade, Serbia
(Stevic); Department of Health Sciences, University
of Eastern Piedmont, Novara, Italy (D’Alfonso,
Corrado); ALS Center, Azienda Ospedaliero
Universitaria Maggiore della Carità, Novara, Italy
(Mazzini); Neurology Unit, IRCCS Foundation Ca’
Granda Ospedale Maggiore Policlinico, Milan, Italy
(Comi, Del Bo, Corti); Department of Brain and
Behavior, University of Pavia, Pavia, Italy (Ceroni);
General Neurology Unit, IRCCSMondino
Association of Variants in the SPTLC1 GeneWith Juvenile Amyotrophic Lateral Sclerosis Original Investigation Research
jamaneurology.com (Reprinted) JAMANeurology October 2021 Volume 78, Number 10 1243
Downloaded From: https://jamanetwork.com/ on 11/29/2021
Foundation, Pavia, Italy (Ceroni); Genomic and
Post-Genomic Center, Mondino Foundation—IRCCS,
Pavia, Italy (Gagliardi, Cereda); Department of
Neurosciences, University of Padova, Padova, Italy
(Querin, Bertolin, Sorarù); Department of
Neurology, Brain Center Rudolf Magnus, University
Medical Center Utrecht, Utrecht, the Netherlands
(van Rheenen, Veldink, van den Berg); Department
of Neuroscience, Mayo Clinic, Jacksonville, Florida
(Rademakers, van Blitterswijk); 3rd Neurology Unit,
Motor Neuron Diseases Center, Fondazione IRCCS
Istituto Neurologico ‘Carlo Besta,’ Milan, Italy
(Giuseppe Lauria); Humanitas Clinical and Research
Center–IRCCS, Milan, Italy (Duga); Department of
Biomedical Sciences, Humanitas University, Milan,
Italy (Duga); Centre for Motor Neuron Disease
Research, Department of Biomedical Sciences,
Faculty of Medicine and Health Sciences, Macquarie
University, Sydney, Australia (Williams, Nicholson,
Blair); Molecular Medicine Laboratory, Clinical
Sciences Building, Concord Hospital, Concord,
Australia (Nicholson); Human Genetics and
Cognitive Functions Unit, Institut Pasteur, Paris,
France (Leblond-Manry); Montreal Neurological
Institute, Department of Neurology and
Neurosurgery, McGill University, Montreal, Quebec,
Canada (Rouleau); Academic Unit of Neurology,
Trinity Biomedical Sciences Institute, Trinity College
Dublin, Dublin, Republic of Ireland (Hardiman);
Faculty of Medicine, Health and Life Sciences,
Queen’s University Belfast, Belfast, United Kingdom
(Morrison); School of Clinical and Experimental
Medicine, University of Birmingham, Birmingham,
United Kingdom (Pall); Sheffield Institute for
Translational Neuroscience, Department of
Neuroscience, University of Sheffield, Sheffield,
United Kingdom (Pamela J. Shaw); Nuffield
Department of Clinical Neurosciences, University of
Oxford, Oxford, United Kingdom (Turner, Talbot);
Department of Bioinformatics and Computational
Biology, Worcester Polytechnic Institute,
Worcester, Massachusetts (Wu); The American
Genome Center, Collaborative Health Initiative
Research Program, Uniformed Services University
of the Health Sciences, Bethesda, Maryland
(Dalgard, Adeleye, Soltis, Alba, Viollet, Bacikova,
Hupalo, Sukumar, Pollard, Wilkerson, Martinez);
Department of Anatomy, Physiology & Genetics,
Uniformed Services University of the Health
Sciences, Bethesda, Maryland (Dalgard, Pollard,
Wilkerson); Henry M. Jackson Foundation for the
Advancement of Military Medicine, Bethesda,
Maryland (Adeleye, Soltis, Alba, Viollet, Bacikova,
Hupalo, Sukumar, Wilkerson, Martinez);
Neuromuscular Diseases Research Section,
Laboratory of Neurogenetics, National Institute on
Aging, Bethesda, Maryland (Abramzon, Chia,
Murphy, Pliner, Renton, Rivera, Traynor); Sobell
Department of Motor Neuroscience andMovement
Disorders, Institute of Neurology, University College
London, London, United Kingdom (Abramzon,
Fratta); Neurodegenerative Diseases Research Unit,
Laboratory of Neurogenetics, National Institute of
Neurological Disorders and Stroke, Bethesda,
Maryland (Ahmed, Geiger, Scholz); Genomics
Technology Group, Laboratory of Neurogenetics,
National Institute on Aging, Bethesda, Maryland
(Arepalli, Hernandez); Department of Neurology,
Cedars-Sinai Medical Center, Los Angeles, California
(Baloh); Division of Neurology, Barrow Neurological
Institute, Phoenix, Arizona (Bowser); Research and
Development Service, Veterans Affairs Boston
Healthcare System, Boston, Massachusetts (Brady);
Centre de Recherche de l’Institut du Cerveau et de
la Moelle épinière, Université Pierre et Marie Curie,
Paris, France (Brice, Le Ber); INSERMU975, Paris,
France (Brice, Le Ber); Department of Biochemistry,
Penn State College of Medicine, Hershey,
Pennsylvania (Broach); Department of Computer
Science, University of Illinois at Urbana-Champaign,
Urbana (Campbell, Faghri); ALS Reference Center,
Gui de Chauliac Hospital, CHU and University of
Montpellier, Montpellier, France (Camu);
Department of Neuroscience, University of
Sheffield, Sheffield, United Kingdom
(Cooper-Knock, Kirby, Pamela J. Shaw);
Computational Biology Group, Laboratory of
Neurogenetics, National Institute on Aging,
Bethesda, Maryland (Ding, Gibbs); Institute for
Clinical Neurobiology, University of Würzburg,
Würzburg, Germany (Drepper); Department of
Neurology, Tel-Aviv Sourasky Medical Center,
Tel-Aviv, Israel (Drory); Neurodegenerative Disease
Research Center, Biodesign Institute, Arizona State
University, Tempe (Dunckley); Department of
Genetics and Pharmacogenomics, Merck Research
Laboratories, Merck, West Point, Pennsylvania
(Eicher, Stone); Human Genetics Branch, National
Institute of Mental Health, Bethesda, Maryland
(England); Molecular Genetics Section, Laboratory
of Neurogenetics, National Institute on Aging,
Bethesda, Maryland (Faghri, Nalls, Singleton);
Department of Neurology, University of Michigan,
Ann Arbor (Feldman); Motor Neuron Disorders
Unit, Laboratory of Neurogenetics, National
Institute of Neurological Disorders and Stroke,
Bethesda, Maryland (Floeter); Department of
Pathology, Penn State College of Medicine,
Hershey, Pennsylvania (Gerhard); Department of
Neurology, University of Utah School of Medicine,
Salt Lake City (Gibson, Pulst); Department of
Neurology, Emory University School of Medicine,
Atlanta, Georgia (Jonathan D. Glass); Department
of Molecular Neuroscience and Reta Lila Weston
Laboratories, Institute of Neurology, University
College London, London, United Kingdom (Hardy,
Sidle, Traynor); Department of Neurology,
Columbia University, New York, New York (Harms);
Department of Neurology, Drexel University
College of Medicine, Philadelphia, Pennsylvania
(Heiman-Patterson); Department of Neurology,
Temple University, Philadelphia, Pennsylvania
(Heiman-Patterson); Department of Neurology,
University of Helsinki, Helsinki, Finland (Jansson,
Laaksovirta, Tienari, Valori); Department of
Neurology, Veterans Affairs Boston Healthcare
System, Boston, Massachusetts (Kowall); Cell
Biology and Gene Expression Section, Laboratory of
Neurogenetics, National Institute on Aging,
Bethesda, Maryland (Landeck, N. Smith);
Department of Geriatrics, Neurosciences and
Orthopedics, Center for Geriatric Medicine, Catholic
University of Sacred Heart, Rome, Italy (Landi);
INM, INSERM, University of Montpellier, CHU
Nîmes, Nîmes, France (Lumbroso, Mouzat);
Neuromuscular Division and ALS Center, Beth Israel
Medical Center, Albert Einstein College of Medicine,
New York, New York (MacGowan); Department of
Neurology, Johns Hopkins University, Baltimore,
Maryland (Maragakis, Ostrow, Rothstein, Scholz,
Traynor); ALS Center, ICS Maugeri, IRCCS, Milan,
Italy (Gabriele Mora); Department of Pathology,
Haartman Institute/HUSLAB, University of Helsinki
and Folkhalsan Research Center (LM), Helsinki,
Finland (Myllykangas); Data Tecnica International,
Glen Echo, Maryland (Nalls); Department of Clinical
Neuroscience, Institute of Neurology, University
College London, London, United Kingdom (Orrell);
Discipline of Pathology, Brain andMind Centre,
University of Sydney, Camperdown, Australia
(Pamphlett); Faculty of Human andMedical
Sciences, University of Manchester, Manchester,
United Kingdom (Pickering-Brown, Rollinson);
Department of Neurology, Cleveland Clinic,
Cleveland, Ohio (Pioro); Clinical and
Neuropathology Core, Johns Hopkins University,
Baltimore, Maryland (Pletnikova, Troncoso);
Department of Neuroscience, Experimental
Neurology and Leuven Research Institute for
Neuroscience and Disease, University of California
San Diego, La Jolla (Ravits); Nash Family
Department of Neuroscience, Ronald M. Loeb
Center for Alzheimer’s Disease, Icahn School of
Medicine at Mount Sinai, New York, New York
(Renton); Department of Neurosciences,
Experimental Neurology and Leuven Research
Institute for Neuroscience and Disease, University
of Leuven, Leuven, Belgium (Robberecht, Van
Damme, Van Den Bosch); Tanz Centre for Research
of Neurodegenerative Diseases, University of
Toronto, Toronto, Ontario, Canada (Rogaeva);
Department of Neurology, Institute for Clinical
Neurobiology, University of Würzburg, Würzburg,
Germany (Sendtner); Department of Neurology,
Penn State College of Medicine, Hershey,
Pennsylvania (Simmons); VIB, Center for Brain &
Disease Research, Laboratory of Neurobiology,
University of Leuven, Leuven, Belgium (Van
Damme); Department of Pathology and Laboratory
Medicine, University of Pennsylvania, Philadelphia
(Van Deerlin); Division of Neurology, Sunnybrook
Health Sciences Centre, University of Toronto,
Toronto, Ontario, Canada (Zinman); Department of
Neurology, University of Massachusetts Medical
School, Worcester (John E. Landers); ‘Rita Levi
Montalcini’ Department of Neuroscience,
University of Turin, Turin, Italy (Adriano Chiò,
Brunetti, Calvo, Canosa, Casale, Adriano Chiò,
DeMarco, Fuda, Gallone, Grassano, Iazzolino,
Manera, Moglia, Salamone, Vasta); Neuroscience
Institute of Torino, University of Turin, Turin, Italy
(Adriano Chiò, Ausiello); National Institute of
Neurological Disorders and Stroke, Bethesda,
Maryland (Traynor); Neurology Unit, AV4 ASUR
Marche, Fermo, Italy (Angelocola, Cardinali);
Department of Medical Genetic, Azienda
Ospedaliero Universitaria Città della Salute e della
Scienza, Torino, Italy (Barberis, Sbaiz); Center for
Diagnosis and Cure of Rare Diseases, Department
of Neurology, IRCCS Institute of Neurological
Sciences, Bologna, Italy (Bartolomei, Salvi,
Vacchiano); Department of Medical, Surgical and
Neurological Sciences, University of Siena, Siena,
Italy (Battistini, Giannini, Ricci, Riolo); 3rd
Neurology Unit andMotor Neuron Diseases Centre,
IRCCS Foundation “Carlo Besta” Neurological
Institute, Milan, Italy (Bersano, Dalla Bella,
Giuseppe Lauria); NeuroMuscular Omnicentre
(NEMO), Serena Onlus, Foundation Pol. A. Gemelli,
Roma, Italy (Bisogni, Conte); Neurologic Unit,
Monserrato University Hospital, Cagliari University,
Cagliari, Italy (Borghero, Cuccu, Floris, Murru,
Tranquilli); Department of Neurosciences,
Rehabilitation, Ophthalmology, Genetics and
Maternal-Child Sciences, IRCCS Ospedale Policlinico
SanMartino, Genoa, Italy (Cabona, Caponnetto,
Ferraro, Mandich, Origone); Division of Neurology,
Azienda Ospedaliero–Universitaria Città della Salute
e della Scienza di Torino, Torino, Italy (Calvo,
Research Original Investigation Association of Variants in the SPTLC1 GeneWith Juvenile Amyotrophic Lateral Sclerosis
1244 JAMANeurology October 2021 Volume 78, Number 10 (Reprinted) jamaneurology.com
Downloaded From: https://jamanetwork.com/ on 11/29/2021
Canosa, Adriano Chiò, Moglia); Department of
AdvancedMedical and Surgical Sciences, University
of Campania “Luigi Vanvitelli,” Caserta, Italy
(Canale); Struttura complessa di
Neurofisiopatologia, Azienda Ospedaliera di
Perugia, Perugia, Italy (Cantisani); Unit of
Neurology, Ospedale Clinicizzato SS Annunziata,
Chieti, Italy (Capasso); Unit of Genomics for the
Diagnosis of Human Pathologies, IRCCS San
Raffaele Scientific Institute, Milan, Italy (Carrera);
ALS Clinical Research Center, BiND, University of
Palermo, Palermo, Italy (Colletti, La Bella, Spataro);
Department of Pharmacy, Health and Nutritional
Sciences, University of Calabria, Rende, Italy
(Conforti); Neurology Unit, “San Gerardo” Hospital,
Monza, Italy (Conti, Ferrarese, Tremolizzo); School
of Medicine and Surgery andMilan Center for
Neuroscience (NeuroMI), University of
Milano-Bicocca, Milan, Italy (Conti, Ferrarese,
Tremolizzo); Department of Neurorehabilitation
Sciences, Casa Cura Policlinico, Milan, Italy (Corbo);
Department of Basic Medical Sciences,
Neurosciences and Sense Organs, University of Bari
“AldoMoro,” Policlinic, Bari, Italy (D’Errico, Introna,
Simone); Department of Neurosciences,
Reproductive Sciences and Odontostomatology,
University of Naples Federico II, Napoli, Italy
(Dubbioso, Manganelli); Neurology Unit and
Rehabilitation Unit, IRCCS “San Raffaele Scientific
Institute,” Milan, Italy (Filippi); Neuroimaging
Research Unit, Division of Neuroscience, IRCCS
“San Raffaele Scientific Institute,” Milan, Italy
(Filippi); Neurophysiology Service, IRCCS “San
Raffaele Scientific Institute,” Milan, Italy (Filippi);
Vita-Salute San Raffaele University, Milan, Italy
(Filippi); Department of Neurosciences, Ospedale
Civile S. Agostino Estense, Azienda Ospedaliero
Universitaria di Modena, Modena, Italy (Fini,
Gianferrari, Mandrioli, Martinelli, Simonini, Zucchi);
NeuroMuscular Omnicentre (NEMO) Clinical Center
Milano, Fondazione Serena Onlus, Milan, Italy
(Greco, Lunetta, Pozzi, Salivetto); Genetica Medica,
Fondazione Policlinico Universitario A. Gemelli
IRCCS, Roma, Italy (Lattante, Marangi);
Dipartimento Universitario Scienze della Vita e
Sanità Pubblica, Sezione di Medicina Genomica,
Università Cattolica del Sacro Cuore Facoltà di
Medicina e Chirurgia, Roma, Italy (Lattante,
Marangi); Department of Biomedical and Clinical
Sciences Luigi Sacco, University of Milan, Milan,
Italy (Giuseppe Lauria); Department of Biomedical
and Neuromotor Sciences, University of Bologna,
Bologna, Italy (Liguori); Department of Basic
Medical Sciences, Neuroscience and Sense Organs,
University of Bari AldoMoro, Bari, Italy
(Logroscino); Center for Neurodegenerative
Diseases and the Aging Brain, Department of
Clinical Research in Neurology, Pia Fondazione
Cardinale G. Panico, Tricase, Italy (Logroscino);
Neurology Unit, AV3, ASURMarche, Macerata, Italy
(Logullo, Petrelli); Medical Genetics Unit, IRCCS
Ospedale Policlinico SanMartino, Genoa, Italy
(Mandich); Department of Neurorehabilitation,
Istituti Clinici Scientifici Maugeri IRCCS, Institute of
Milan, Milan, Italy (Marinou, Gabriele Mora, Sideri);
Department of Neurology, Azienda Universitario
Ospedaliera di Cagliari and University of Cagliari,
Cagliari, Italy (Marrosu); NeuroMuscular
Omnicentre (NEMO) Sud, Fondazione Aurora, OUC
Neurology and Neuromuscular Disorders,
University of Messina, Messina, Italy (Messina);
Department of Laboratory Medicine, Medical
Genetics, Niguarda Ca’ Granda Hospital, Milan, Italy
(Mosca); Department of AdvancedMedical and
Surgical Sciences, University of Campania “Luigi
Vanvitelli,” Napoli, Italy (Passaniti, Tedeschi, Trojsi);
Neurology Department, San Camillo Hospital,
Roma, Italy (Petrucci); Department of Biomedical
and Surgical Sciences, Section of Neurological,
Psychiatric and Psychological Sciences, University
of Ferrara, Ferrara, Italy (Pugliatti); Department of
Neurology, IRCCS “San Raffaele Scientific Institute,”
Milan, Italy (Quattrini, Riva); OUC Neurology and
Neuromuscular Disorders, University of Messina,
Messina, Italy (Russo, Vita); NeuroMuscular
Omnicentre (NEMO)–Fondazione Policlinico
Universitario A. Gemelli, Università Cattolica del
Sacro Cuore, Roma, Italy (Sabatelli); Department of
Medicine, Azienda Complesso Ospedaliero,
San Filippo Neri, Roma, Italy (Santarelli); Operative
Unit of Neurology, S. Chiara Hospital, Trento, Italy
(Tanel); Department of Neurology, Azienda
Ospedaliera San Francesco, Nuoro, Italy (Ticca);
ALS Center, Operative Unit of Neurology, AOU
“San Giovanni di Dio e Ruggi d’Aragona,” Salerno,
Italy (Torriello); Neurorehabilitation Unit–ALS
Center, Istituti Clinici Scientifici (ICS) Maugeri,
Mistretta, Italy (Volanti); Sezione di Medicina
Genomica, Dipartimento Scienze della Vita e Sanità
Pubblica, Facoltà di Medicina e Chirurgia, Università
Cattolica Sacro Cuore, Roma, Italy (Zollino); Unità di
Genetica Medica, Fondazione Policlinico
Universitario A. Gemelli IRCCS, Roma, Italy (Zollino).
Author Contributions: Dr Traynor had full access
to all of the data in the study and takes
responsibility for the integrity of the data and the
accuracy of the data analysis. Drs Johnson, Chia,
Miller, Li, Kumaran, Abramzon, Alahmady, Basak,
Landers, Chiò, Crawford, B. Smith, and Traynor
contributed equally to this article.
Study concept and design: Chia, Kumaran,
Abramzon, Cookson, Al Khleifat, Gotkine, I. Glass,
Landers, Chiò, Crawford, B. Smith, Traynor, Arepalli,
Fallini, Cereda, Pollard, Campbell, Hardy,
Laaksovirta, Singleton, Van Deerlin, Ceroni,
García-Redondo, Cantisani, Cardinali, Logroscino,
Lunetta, Origone, Brice, Ricci, Riolo, Salivetto.
Acquisition, analysis, or interpretation of data:
Johnson, Chia, Miller, Li, Kumaran, Abramzon,
Alahmady, Renton, Topp, Gibbs, Sabir, Dalgard,
Troakes, Jones, Shatunov, Iacoangeli, Al Khleifat,
Ticozzi, Silani, Gellera, Blair, Dobson-Stone, Kwok,
Bonkowski, Palvadeau, Tienari, Morrison, P. Shaw,
Al-Chalabi, Brown, Calvo, Mora, Al Saif, Gotkine,
Leigh, Chang, Perlman, I. Glass, Scott, C. Shaw,
Başak, Chiò, Crawford, B. Smith, Traynor, Ratti,
Soltis, Castellotti, England, Alba, Vance, Brady,
Bertolin, Tiloca, Leblond-Manry, Colombrita, Viollet,
Bacikova, Hupalo, Stone, Sukumar, Pollard,
Wilkerson, Martinez, Baloh, Broach, Camu,
Cooper-Knock, Ding, Drepper, Drory, Dunckley,
Eicher, Faghri, Feldman, Floeter, Fratta, Geiger,
Gerhard, Gibson, J. Glass, Harms,
Heiman-Patterson, Hernandez, Jansson, Kirby,
Kowall, Landi, Le Ber, Lumbroso, MacGowan,
Maragakis, Mouzat, Murphy, Myllykangas, Nalls,
Orrell, Ostrow, Pamphlett, Pickering-Brown, Pioro,
Pliner, Pulst, Ravits, Robberecht, Rogaeva,
Rollinson, Rothstein, Scholz, Sendtner, Sidle,
Simmons, Troncoso, Valori, Van Damme,
Van Den Bosch, Zinman, N. Smith, Landeck,
Pletnikova, Ahmed, Scotter, Kenna, Keagle,
Pensato, Baas, McKenna-Yasek, Mclaughlin, Polak,
Asress, Esteban-Pérez, Stevic, D’Alfonso, Mazzini,
Comi, Del Bo, Gagliardi, Querin, van Rheenen,
Rademakers, Van Blitterswijk, Duga, Corti, Corrado,
Sorarù, Williams, Nicholson, Rouleau, Hardiman,
Veldink, van den Berg, Pall, Turner, Talbot, Taroni,
Wu, Angelocola, Ausiello, Barberis, Bartolomei,
Battistini, Bersano, Borghero, Brunetti, Cabona,
Canale, Canosa, Capasso, Caponnetto, Carrera,
Casale, Colletti, Conforti, Conte, Conti, Corbo,
Cuccu, Dalla Bella, D’errico, DeMarco, Dubbioso,
Ferrarese, Ferraro, Filippi, Fini, Floris, Fuda, Gallone,
Gianferrari, Giannini, Grassano, Greco, Iazzolino,
Introna, La Bella, Lattante, Lauria, Liguori, Logullo,
Lunetta, Mandich, Mandrioli, Manera, Manganelli,
Marangi, Marinou, Marrosu, Martinelli, Messina,
Moglia, Mosca, Murru, Passaniti, Petrelli, Petrucci,
ten Asbroek, Gkazi, Adeleye, Rivera, King, Bisogni,
Pozzi, Pugliatti, Quattrini, Riva, Russo, Sabatelli,
Salamone, Salvi, Santarelli, Sbaiz, Sideri, Simone,
Simonini, Spataro, Tanel, Tedeschi, Ticca, Toriello,
Tranquilli, Tremolizzo, Trojsi, Vacchiano, Vasta, Vita,
Volanti, Zollino, Zucchi, Bowser.
Drafting of the manuscript: Chia, Miller, Kumaran,
Al Khleifat, Gellera, Kwok, Chang, Crawford,
B. Smith, Traynor, Arepalli, Pollard, Campbell,
Heiman-Patterson, Laaksovirta, Sidle, Pensato,
McKenna-Yasek, Angelocola, Brunetti, Cantisani,
Caponnetto, Conti, Floris, Greco, Petrelli, Riva,
Salivetto, Sbaiz.
Critical revision of the manuscript for important
intellectual content: Johnson, Chia, Li, Kumaran,
Abramzon, Alahmady, Renton, Topp, Gibbs,
Cookson, Sabir, Dalgard, Troakes, Jones, Shatunov,
Iacoangeli, Al Khleifat, Ticozzi, Silani, Blair,
Dobson-Stone, Bonkowski, Palvadeau, Tienari,
Morrison, P. Shaw, Al-Chalabi, Brown, Calvo, Mora,
Al Saif, Gotkine, Leigh, Perlman, I. Glass, Scott,
C. Shaw, Başak, Landers, Chiò, Crawford, B. Smith,
Traynor, Ratti, Soltis, Castellotti, England, Alba,
Vance, Fallini, Brady, Bertolin, Tiloca,
Leblond-Manry, Colombrita, Viollet, Cereda,
Bacikova, Hupalo, Stone, Sukumar, Pollard,
Wilkerson, Martinez, Baloh, Broach, Camu,
Cooper-Knock, Ding, Drepper, Drory, Dunckley,
Eicher, Faghri, Feldman, Floeter, Fratta, Geiger,
Gerhard, Gibson, J. Glass, Hardy, Harms,
Hernandez, Jansson, Kirby, Kowall, Landi, Le Ber,
Lumbroso, MacGowan, Maragakis, Mouzat,
Murphy, Myllykangas, Nalls, Orrell, Ostrow,
Pamphlett, Pickering-Brown, Pioro, Pliner, Pulst,
Ravits, Robberecht, Rogaeva, Rollinson, Rothstein,
Scholz, Sendtner, Simmons, Singleton, Troncoso,
Valori, Van Damme, Van Deerlin, Van Den Bosch,
Zinman, N. Smith, Landeck, Pletnikova, Ahmed,
Scotter, Kenna, Keagle, Baas, Mclaughlin, Polak,
Asress, Esteban-Pérez, Stevic, D’Alfonso, Mazzini,
Comi, Del Bo, Ceroni, Gagliardi, Querin,
van Rheenen, Rademakers, Van Blitterswijk, Duga,
Corti, Corrado, Sorarù, Williams, Nicholson,
Rouleau, Hardiman, Veldink, van den Berg, Pall,
Turner, Talbot, Taroni, García-Redondo, Wu,
Ausiello, Barberis, Bartolomei, Battistini, Bersano,
Borghero, Cabona, Canale, Canosa, Capasso,
Cardinali, Carrera, Casale, Colletti, Conforti, Conte,
Corbo, Cuccu, Dalla Bella, D’errico, DeMarco,
Dubbioso, Ferrarese, Ferraro, Filippi, Fini, Floris,
Fuda, Gallone, Gianferrari, Giannini, Grassano,
Iazzolino, Introna, La Bella, Lattante, Lauria, Liguori,
Logroscino, Logullo, Lunetta, Mandich, Mandrioli,
Manera, Manganelli, Marangi, Marinou, Marrosu,
Martinelli, Messina, Moglia, Mosca, Murru, Origone,
Passaniti, Petrucci, ten Asbroek, Gkazi, Adeleye,
Rivera, Brice, King, Bisogni, Pozzi, Pugliatti,
Quattrini, Ricci, Riolo, Riva, Russo, Sabatelli,
Salamone, Salvi, Santarelli, Sideri, Simone,
Simonini, Spataro, Tanel, Tedeschi, Ticca, Toriello,
Association of Variants in the SPTLC1 GeneWith Juvenile Amyotrophic Lateral Sclerosis Original Investigation Research
jamaneurology.com (Reprinted) JAMANeurology October 2021 Volume 78, Number 10 1245
Downloaded From: https://jamanetwork.com/ on 11/29/2021
Tranquilli, Tremolizzo, Trojsi, Vacchiano, Vasta, Vita,
Volanti, Zollino, Zucchi, Bowser.
Statistical analysis: Johnson, Chia, Kumaran,
Abramzon, Topp, Gibbs, Sabir, Calvo, Traynor,
England, Pollard, Martinez, Ding, Faghri, Geiger,
Nalls, Tranquilli.
Obtained funding: Kwok, Al-Chalabi, Gotkine,
C. Shaw, Traynor, Stone, Pollard, Hardy, Kowall,
Pulst, Rogaeva, Baas, Stevic, D’Alfonso,
van den Berg, Taroni, Gallone.
Administrative, technical, or material support: Chia,
Gibbs, Dalgard, Troakes, Jones, Iacoangeli,
Al Khleifat, Tienari, Morrison, Al-Chalabi, Brown,
Gotkine, Perlman, I. Glass, Scott, C. Shaw, Başak,
Landers, Crawford, B. Smith, Traynor, Ratti, Soltis,
Castellotti, Alba, Brady, Tiloca, Viollet, Bacikova,
Hupalo, Sukumar, Pollard, Wilkerson, Camu,
Cooper-Knock, Drepper, Dunckley, Eicher, Fratta,
Geiger, Gibson, J. Glass, Hernandez, Jansson, Kirby,
Kowall, Laaksovirta, MacGowan, Maragakis,
Murphy, Myllykangas, Nalls, Orrell, Ostrow,
Pamphlett, Pickering-Brown, Pioro, Rollinson,
Rothstein, Scholz, Sendtner, Sidle, Simmons,
Van Deerlin, Zinman, N. Smith, Landeck, Pletnikova,
Keagle, Baas, McKenna-Yasek, Asress, D’Alfonso,
Del Bo, Gagliardi, Corrado, Rouleau,
García-Redondo, Angelocola, Barberis, Bersano,
Canale, Canosa, Casale, Conti, Cuccu, Dalla Bella,
DeMarco, Dubbioso, Floris, Fuda, Grassano,
Introna, Lauria, Mandrioli, Manera, Murru,
ten Asbroek, Gkazi, Adeleye, Brice, King, Pugliatti,
Riva, Zollino, Bowser.
Study supervision: Cookson, Silani, Blair, Tienari,
Al-Chalabi, Leigh, I. Glass, C. Shaw, Landers, Chiò,
Traynor, Fallini, Baloh, MacGowan, Nalls, Scholz,
Mazzini, Ceroni, Taroni, Ausiello, Cabona,
Caponnetto, Cardinali, Ferraro, Floris, Logroscino,
Logullo, Manganelli, Marinou, Marrosu, Messina,
Riva, Russo, Simone, Tedeschi, Vita.
Conflict of Interest Disclosures:Drs Tienari and
Traynor hold the US, Canadian, and European
patents on the clinical testing and therapeutic
intervention for the hexanucleotide repeat
expansion in C9orf72. Dr Chiò serves on scientific
advisory boards for Biogen Idec, Cytokinetics,
Italfarmaco, and Neuraltus. Dr Al-Chalabi reports
consultancies for Biogen Idec, Cytokinetics Inc,
OrionPharma, Chronos Therapeutics, and
Mitsubishi-Tanabe Pharma. Dr Landers is a member
of the scientific advisory board for Cerevel
Therapeutics and a consultant and provides expert
testimony for Perkins Coie. Dr Topp reports grants
fromUK Dementia Research Institute during the
conduct of the study. Dr Dobson-Stone reports
grants fromNational Health andMedical Research
Council of Australia during the conduct of the study.
Dr Kwok reports grants fromNational Health and
Medical Research Council during the conduct of the
study. Dr Tienari reports grants from Sigrid Juselius
Foundation and Helsinki University Hospital during
the conduct of the study. Dr Al-Chalabi reports
grants from the UKMedical Research Council
during the conduct of the study and has consulted
for Biogen Idec, OrionPharma, Amylyx, BrainStorm,
Mitsubishi Tanabe Pharma, Cytokinetics, and
Apellis outside the submitted work. Dr Landers
reports grants from the ALS Association and
National Institute of Neurological Disorders and
Stroke during the conduct of the study as well as
personal fees from Cerevel Therapeutics and
Perkins Coie outside the submitted work. Dr Chiò
reports personal fees from Biogen Scientific and
Cytokinetics Scientific outside the submitted work.
Dr Traynor reports institutional support from
Intramural Program of the National Institutes
of Health; and grants from Packard Center, ALS
Association, andMuscular Dystrophy Association
during the conduct of the study; grants from
Myasthenia Gravis foundation, Merck, US Centers
for Disease Control and Prevention, US Veterans
Administration, andMicrosoft Research outside
the submitted work; and is on the editorial board
of JAMA Neurology; Journal of Neurology,
Neurosurgery, and Psychiatry; Neurobiology of
Aging; and Brain. Dr Stone is an employee of
Cerevel Therapeutics. Dr Pollard reports grants
from the National Institutes of Health during the
conduct of the study. Dr Baloh is employed by
Roche Pharmaceuticals. Dr Eicher is an employee
of Merck and GlaxoSmithKline. Dr Faghri reports
personal fees fromNational Institutes of Health
outside the submitted work. Dr Feldman reports
grants from the National Institutes of Health,
US Centers for Disease Control and Prevention/
Agency for Toxic Substances and Disease Registry,
Novo Nordisk Foundation, and JDRF and personal
fees fromNovartis outside the submitted work.
Dr Geiger reports personal fees from the National
Institutes of Health during the conduct of the study.
Dr Harms reports grants from Biogen, ALS
Association, and Project ALS during the conduct
of the study as well as personal fees from Invitae
and VariantBio outside the submitted work.
Dr Heiman-Patterson reports grants from
Mitsubishi Tanabe America and personal fees from
Samus, Cytokinetics, ITF, and Orion outside the
submitted work. Dr Le Ber reports grants from
PHRC FTLD-exome and Investissements d’avenir
during the conduct of the study as well as personal
fees from Prevail Therapeutics and Alector outside
the submitted work. Dr Maragakis reports grants
fromUS Department of Defense and Answer ALS
during the conduct of the study. Dr Murphy reports
salary support fromNational Institute on Aging
during the conduct of the study. Dr Nalls reports
support from the National Institutes of Health.
Dr Orrell reports grants fromMotor Neurone
Disease Association during the conduct of the
study. Dr Ostrow reports grants from Target ALS
Foundation during the conduct of the study and
grants from ALS Association outside the submitted
work. Dr Rothstein reports grants from Calico
Therapeutics and GlaxoSmith Kline; personal fees
from Expansion Therapeutics; and nonfinancial
support from Ionis Pharmaceuticals outside the
submitted work. Dr Scholz reports serving on
editorial boards of the Journal of Parkinson’s
Disease, Frontiers in Neurology, Frontiers in
Neuroscience, Frontiers in Psychiatry, and JAMA
Neurology. Dr Simmons reports personal fees from
Biogen, Amylyx, and Alexion and grants from
MT Pharma outside the submitted work.
Dr Troncoso reports grants from the National
Institutes of Health Alzheimer’s Disease Research
Center during the conduct of the study.
Dr Van Damme reports grants from CSL Behring
and fees from Biogen, Alexion Pharmaceuticals,
Ferrer, QurAlis, and Argenx paid to his institution
outside the submitted work. Dr Baas reports
personal fees from ComplementPharma outside
the submitted work. Dr Hardiman reports grants
from Science Foundation Ireland during the
conduct of the study as well as personal fees from
Taylor & Francis outside the submitted work.
Dr Veldink reports grants from Biogen outside the
submitted work. Dr van den Berg reports grants
fromNetherlands ALS Foundation during the
conduct of the study. Dr Turner reports grants from
Motor Neurone Disease Association as well as
personal fees fromOrphazyme, Oxford University
Press, and BMA Journals outside the submitted
work. Dr Taroni reports grants from Italian Ministry
of Health during the conduct of the study as well
as grants from Italian Ministry of Health and
Fondazione Regionale per la Ricerca Biomedica
(FRRB) outside the submitted work. Dr Corbo
reports personal fees from Biogen outside the
submitted work. Dr Filippi reports personal fees
from Almiral, Alexion, Bayer, Biogen, Celgene,
Eli Lilly, Genzyme, Merck-Serono, Novartis, Roche,
Sanofi, Takeda, and Teva; grants from Biogen,
Merck-Serono, Novartis, Roche, and Teva outside
the submitted work; and is Editor-in-Chief of the
Journal of Neurology and Associate Editor ofHuman
Brain Mapping. Dr Liguori reports personal fees
from ARGENX BV outside the submitted work.
Dr Mandrioli reports nonfinancial support from
Pfizer outside the submitted work. Dr Brice reports
grants from Institut de France Prix de Recherche
Allianz 2018, ANR–EPIC, France Parkinson + FRC,
and APHP Extraction d’ADN à partir de
prélèvements sanguins, conservation des
échantillons d’ADN extraits et distributions
d’aliquots d’ADN pour analyse outside the
submitted work. Dr Bisogni reports personal fees
from Alnylam outside the submitted work.
Dr Tedeschi reports grants from Roche, Biogen,
Allergan, Merck, Novartis, and Lilly outside the
submitted work. Dr Bowser reports personal fees
from Iron Horse Diagnostics outside the submitted
work. No other disclosures were reported.
Funding/Support: This work was supported in
part by the Intramural Research Programs of the
National Institute on Aging (grant
Z01-AG000949-02) and National Institute of
Neurological Disorders and Stroke (grant
ZIA-NS03154). The work was also funded by the
Packard Center for ALS Research at Johns Hopkins,
the ALS Association (grant 20-SI-508), the
Muscular Dystrophy Association, the Italian
Ministry of Health (grant RF-2016-02362405),
the Italian Ministry of Education, University and
Research (Progetti di Ricerca di Rilevante Interesse
Nazionale [PRIN]; grant 2017SNW5MB), the Joint
Programme–Neurodegenerative Disease Research
(JPND; Brain-Mend projects) granted by Italian
Ministry of Education, University and Research, and
by the European Community’s Health Seventh
Framework Programme (FP7/2007–2013; grant
agreements 259867 and 278611), by the National
Institute of Neurological Disorders and Stroke
(grants R35 NS097261, R01NS073873, and
R56NS073873), and by the Collaborative Health
Initiative Research Program. This study was
performed under the Department of Excellence
grant of the Italian Ministry of Education, University
and Research to the ‘Rita Levi Montalcini’
Department of Neuroscience, University of Torino,
Italy. Additional funding was also provided by the
Motor Neurone Disease Association (MNDA), the
Medical Research Council, the Medical Research
Foundation (MRF), the Van Geest Foundation,
The Psychiatry Research Trust of the Institute of
Psychiatry, Guy’s and St. Thomas’ Charity and the
NoreenMurray Foundation, the Sigrid Juselius
Foundation, the UK Dementia Research Institute,
the National Health andMedical Research Council
of Australia (grants 1095215 and 1092023), and
through the following funding organization under
Research Original Investigation Association of Variants in the SPTLC1 GeneWith Juvenile Amyotrophic Lateral Sclerosis
1246 JAMANeurology October 2021 Volume 78, Number 10 (Reprinted) jamaneurology.com
Downloaded From: https://jamanetwork.com/ on 11/29/2021
the aegis of JPND: UKMedical Research Council
(grants MR/L501529/1 andMR/R024804/1). This
work was supported by the Canadian Consortium
on Neurodegeneration in Aging, UK Dementia
Research Institute, which is funded by theMedical
Research Council, Alzheimer’s Society and
Alzheimer’s Research UK. Dr Al-Chalabi is
supported by the National Institute for Health
Research (NIHR) Maudsley Biomedical Research
Centre. Dr P. Shaw is supported as an NIHR Senior
Investigator and by the Sheffield NIHR Biomedical
Research Centre. Dr Dobson-Stone is supported
by the Australian National Health andMedical
Research Council (NHMRC) Boosting Dementia
Research Leadership Fellowship 1138223 and by
the University of Sydney. Dr Kwok is supported by
NHMRC Dementia Research TeamGrant 1095127.
The Alzheimer’s Disease Sequencing Project (ADSP)
is comprised of 2 Alzheimer’s Disease (AD) genetics
consortia and 3 National Human Genome Research
Institute (NHGRI)–funded Large-Scale Sequencing
and Analysis Centers (LSAC). The 2 AD genetics
consortia are the Alzheimer’s Disease Genetics
Consortium (ADGC) funded by National Institute
on Aging grant U01 AG032984, and the Cohorts
for Heart and Aging Research in Genomic
Epidemiology (CHARGE) funded by National
Institute on Aging grant R01 AG033193, the
National Heart, Lung, and Blood Institute, other
National Institutes of Health institutes, and other
foreign governmental and nongovernmental
organizations. The Discovery Phase analysis of
sequence data is supported through UF1AG047133
to Drs Schellenberg, Farrer, Pericak-Vance, Mayeux,
and Haines; U01AG049505 to Dr Seshadri;
U01AG049506 to Dr Boerwinkle; U01AG049507
to DrWijsman; and U01AG049508 to Dr Goate.
The Discovery Extension Phase analysis is
supported through U01AG052411 to Dr Goate,
U01AG052410 to Dr Pericak-Vance, and
U01 AG052409 to Drs Seshadri and Fornage. Data
generation and harmonization in the Follow-up
Phases is supported by U54AG052427 (to
Drs Schellenberg andWang). The ADGC cohorts
include Adult Changes in Thought (ACT), the
Alzheimer’s Disease Centers (ADC), the Chicago
Health and Aging Project (CHAP), the Memory and
Aging Project (MAP), Mayo Clinic, Mayo Parkinson’s
Disease controls, University of Miami, the
Multi-Institutional Research in Alzheimer’s Genetic
Epidemiology Study (MIRAGE), the National Cell
Repository for Alzheimer’s Disease (NCRAD), the
National Institute on Aging Late Onset Alzheimer’s
Disease Family Study (NIA-LOAD), the Religious
Orders Study (ROS), the Texas Alzheimer’s
Research and Care Consortium (TARC), Vanderbilt
University/CaseWestern Reserve University
(VAN/CWRU), theWashington Heights-Inwood
Columbia Aging Project (WHICAP) and the
Washington University Sequencing Project (WUSP),
the Columbia University Hispanic–Estudio Familiar
de Influencia Genetica de Alzheimer (EFIGA), the
University of Toronto, and Genetic Differences
(GD). The CHARGE cohorts are supported in part
by National Heart, Lung, and Blood Institute
infrastructure grant HL105756 (Psaty),
RC2HL102419 (Boerwinkle), and the Neurology
Working Group is supported by the National
Institute on Aging R01 grant AG033193. The
CHARGE cohorts participating in the ADSP include
the following: Austrian Stroke Prevention Study
(ASPS), ASPS-Family study, and the Prospective
Dementia Registry-Austria (ASPS/PRODEM-Aus),
the Atherosclerosis Risk in Communities (ARIC)
Study, the Cardiovascular Health Study (CHS),
the Erasmus Rucphen Family Study (ERF), the
FraminghamHeart Study (FHS), and the Rotterdam
Study (RS). ASPS is funded by the Austrian Science
Fund (FWF) grants P20545-P05 and P13180 and
theMedical University of Graz. The ASPS-Fam is
funded by the Austrian Science Fund (FWF) project
I904, the EU Joint Programme–Neurodegenerative
Disease Research (JPND) in frame of the BRIDGET
project (Austria, Ministry of Science) and the
Medical University of Graz and the Steiermärkische
Krankenanstalten Gesellschaft. PRODEM–Austria is
supported by the Austrian Research Promotion
agency (FFG) (project 827462) and by the Austrian
National Bank (Anniversary Fund; project 15435).
ARIC research is carried out as a collaborative study





HHSN268201100012C). Neurocognitive data in
ARIC is collected by U01 2U01HL096812,
2U01HL096814, 2U01HL096899,
2U01HL096902, and 2U01HL096917 from the
National Institutes of Health, and with previous
brain magnetic resonance imaging examinations
funded by R01-HL70825 from the National Heart,
Lung, and Blood Institute. CHS research was
supported by contracts HHSN268201200036C,
HHSN268200800007C, N01HC55222,
N01HC85079, N01HC85080, N01HC85081,
N01HC85082, N01HC85083, and N01HC85086
and grants U01HL080295 and U01HL130114 from
the National Heart, Lung, and Blood Institute, with
additional contribution from the National Institute
of Neurological Disorders and Stroke. Additional
support was provided by R01AG023629,
R01AG15928, and R01AG20098 from the National
Institute on Aging. FHS research is supported by
National Heart, Lung, and Blood Institute contracts
N01-HC-25195 and HHSN268201500001I. This
study was also supported by additional grants from
the National Institute on Aging (R01s AG054076,
AG049607, and AG033040) and National Institute
of Neurological Disorders and Stroke (R01
NS017950). The ERF study as a part of EUROSPAN
(European Special Populations Research Network)
was supported by European Commission FP6 STRP
grant 018947 (LSHG-CT-2006-01947) and also
received funding from the European Community’s
Seventh Framework Programme (FP7/2007-2013)
and grant agreement HEALTH-F4-2007-201413 by
the European Commission under the programme
“Quality of Life andManagement of the Living
Resources” of 5th Framework Programme (No.
QLG2-CT-2002-01254). High-throughput analysis
of the ERF data was supported by a joint grant from
the Netherlands Organization for Scientific
Research and the Russian Foundation for Basic
Research (NWO-RFBR 047.017.043). The
Rotterdam Study is funded by ErasmusMedical
Center and Erasmus University, Rotterdam, the
Netherlands Organization for Health Research and
Development (ZonMw), the Research Institute for
Diseases in the Elderly (RIDE), the Ministry of
Education, Culture and Science, the Ministry for
Health, Welfare and Sports, the European
Commission (DG XII), and themunicipality of
Rotterdam. Genetic data sets are also supported by
the Netherlands Organization of Scientific Research
NWO Investments (175.010.2005.011; 911-03-012),
the Genetic Laboratory of the Department of
Internal Medicine, ErasmusMC, the Research
Institute for Diseases in the Elderly (014-93-015;
RIDE2), and the Netherlands Genomics Initiative
(NGI)/Netherlands Organization for Scientific
Research (NWO) Netherlands Consortium for
Healthy Aging (NCHA; project 050-060-810).
All studies are grateful to their participants, faculty,
and staff. The content of these articles is solely the
responsibility of the authors and does not
necessarily represent the official views of the
National Institutes of Health or the US Department
of Health and Human Services. The 4 Large-Scale
Sequencing and Analysis Centers are the Human
Genome Sequencing Center at the Baylor College of
Medicine (U54 HG003273), the Broad Institute
Genome Center (U54HG003067), The American
Genome Center at the Uniformed Services
University of the Health Sciences (U01AG057659),
and theWashington University Genome Institute
(U54HG003079). Biological samples, and
associated phenotypic data used in primary data
analyses were stored at study investigators’
institutions and at the National Cell Repository for
Alzheimer’s Disease (NCRAD; U24AG021886) at
Indiana University funded by National Institute on
Aging. Associated phenotypic data used in primary
and secondary data analyses were provided by
study investigators, the National Institute on
Aging–funded Alzheimer’s Disease Centers (ADCs),
and the National Alzheimer’s Coordinating Center
(NACC; U01AG016976) and the National Institute
on Aging Genetics of Alzheimer’s Disease Data
Storage Site (NIAGADS; U24AG041689) at the
University of Pennsylvania, funded by the National
Institute on Aging, and at the Database for
Genotypes and Phenotypes (dbGaP; phs000572)
funded by National Institutes of Health. This
research was supported in part by the Intramural
Research Program of the National Institutes of
Health, National Library of Medicine. Contributors
to the Genetic Analysis Data included study
investigators on projects that were individually
funded by the National Institute on Aging and other
National Institutes of Health institutes, and by
private US organizations or foreign governmental or
nongovernmental organizations. Drs Ticozzi, Silani,
and Gellera were financially supported by the Italian
Ministry of Health (grant RF-201302355764).
Ms Palvadeau and Dr Basak’s research was funded
by Suna and Inan Kirac Foundation, grant
2005-2023. The American Genome Center is
supported by National Heart, Lung, and Blood
Institute grant IAA-A-HL-007.001, the Defense
Health Agency, and the Henry M. Jackson
Foundation for the Advancement of Military
Medicine.
Role of the Funder/Sponsor: The funders had no
role in the design and conduct of the study;
collection, management, analysis, and
interpretation of the data; preparation, review, or
approval of themanuscript; and decision to submit
themanuscript for publication.
Disclaimer: The opinions and assertions expressed
herein are those of the author(s) and do not
necessarily reflect the official policy or position
of the Uniformed Services University or the
US Department of Defense.
Additional Contributions:We thank patients 1
and 4 and the parents of patient 3 for granting
permission to publish this information. We thank
the patients and their families for their participation
Association of Variants in the SPTLC1 GeneWith Juvenile Amyotrophic Lateral Sclerosis Original Investigation Research
jamaneurology.com (Reprinted) JAMANeurology October 2021 Volume 78, Number 10 1247
Downloaded From: https://jamanetwork.com/ on 11/29/2021
in our research. We also thank Kirsty McWalter, MS,
and other staff of GeneDx, Gaithersburg, Maryland,
for their assistance. This study used DNA samples,
genotype data, and clinical data from the National
Institute of Neurological Disorders and Stroke
Repository at Coriell, the New York Brain Bank–
The Taub Institute, Columbia University,
Department of Veterans Affairs Biorepository Brain
Bank (grant BX002466), the Baltimore
Longitudinal Study of Aging, the Johns Hopkins
University Alzheimer’s Disease Research Center
(National Institutes of Health grant P50AG05146),
the National Institute of Child Health and Human
Development Brain and Tissue Bank for
Developmental Disorders at the University of
Maryland, the MRC London Neurodegenerative
Diseases Brain Bank, King’s College London, and the
Alzheimer’s Disease Sequencing Project. Samples
used in this research were obtained from the UK
MND Collections funded by theMND Association
and theWellcome Trust. We thank the Suna and
Inan Kirac Foundation for its dedicatedmentorship
and sustained support. We also thank the Koc
University, Jan Veldink, MD (Department of
Neurology, Brain Center Rudolf Magnus, University
Medical Center Utrecht, Utrecht, the Netherlands),
the Project MinE sequencing Consortium, Irmak
Sahbaz, BSc, andMuge Kovancilar-Koc, MSc (Suna
and Inan Kırac Foundation, Neurodegeneration
Research Laboratory, KUTTAM, School of Medicine,
Koc University, Istanbul, Turkey), the
Neurodegeneration Research Laboratory staff,
and the Laboratory of Neurogenetics (National
Institutes of Health) staff for their collegial support
and technical assistance. None of the contributors
were compensated for their work.
REFERENCES
1. Chiò A, Logroscino G, Traynor BJ, et al. Global
epidemiology of amyotrophic lateral sclerosis:
a systematic review of the published literature.
Neuroepidemiology. 2013;41(2):118-130. doi:10.1159/
000351153
2. Orban P, Devon RS, HaydenMR, Leavitt BR.
Chapter 15: juvenile amyotrophic lateral sclerosis.
Handb Clin Neurol. 2007;82:301-312. doi:10.1016/
S0072-9752(07)80018-2
3. Chia R, Chiò A, Traynor BJ. Novel genes
associated with amyotrophic lateral sclerosis:
diagnostic and clinical implications. Lancet Neurol.
2018;17(1):94-102. doi:10.1016/S1474-4422(17)
30401-5
4. Littler M, Morton NE. Segregation analysis of
peripheral neurofibromatosis (NF1). J Med Genet.
1990;27(5):307-310. doi:10.1136/jmg.27.5.307
5. Tuffery-Giraud S, Béroud C, Leturcq F, et al.
Genotype-phenotype analysis in 2,405 patients
with a dystrophinopathy using the UMD-DMD
database: a model of nationwide knowledgebase.
HumMutat. 2009;30(6):934-945. doi:10.1002/
humu.20976
6. Alexander MD, Traynor BJ, Miller N, et al.
“True” sporadic ALS associated with a novel SOD-1
mutation. Ann Neurol. 2002;52(5):680-683.
doi:10.1002/ana.10369
7. Chiò A, Calvo A, Moglia C, et al. A de novo
missensemutation of the FUS gene in a “true”
sporadic ALS case. Neurobiol Aging. 2011;32(3):
553.e23-553.e26.
8. Acuna-Hidalgo R, Veltman JA, Hoischen A.
New insights into the generation and role of de
novomutations in health and disease. Genome Biol.
2016;17(1):241. doi:10.1186/s13059-016-1110-1
9. Brooks BR, Miller RG, SwashM, Munsat TL;
World Federation of Neurology Research Group
onMotor Neuron Diseases. El Escorial revisited:
revised criteria for the diagnosis of amyotrophic
lateral sclerosis. Amyotroph Lateral Scler Other
Motor Neuron Disord. 2000;1(5):293-299.
doi:10.1080/146608200300079536
10. Retterer K, Juusola J, ChoMT, et al. Clinical
application of whole-exome sequencing across
clinical indications.Genet Med. 2016;18(7):696-704.
doi:10.1038/gim.2015.148
11. Project MinE ALS Sequencing Consortium.
Project MinE: study design and pilot analyses of
a large-scale whole-genome sequencing study in
amyotrophic lateral sclerosis. Eur J HumGenet.
2018;26(10):1537-1546. doi:10.1038/s41431-018-
0177-4
12. Raczy C, Petrovski R, Saunders CT, et al.
Isaac: ultra-fast whole-genome secondary analysis
on Illumina sequencing platforms. Bioinformatics.
2013;29(16):2041-2043. doi:10.1093/bioinformatics/
btt314
13. Anderson D, Lassmann T. A phenotype centric
benchmark of variant prioritisation tools.NPJ
GenomMed. 2018;3:5. doi:10.1038/s41525-018-
0044-9
14. GuoMH, Plummer L, Chan YM, Hirschhorn JN,
Lippincott MF. Burden testing of rare variants
identified through exome sequencing via publicly
available control data. Am J HumGenet. 2018;103
(4):522-534. doi:10.1016/j.ajhg.2018.08.016
15. Pilpel N, Landeck N, KlugmannM, Seeburg PH,
Schwarz MK. Rapid, reproducible transduction of
select forebrain regions by targeted recombinant
virus injection into the neonatal mouse brain.
J Neurosci Methods. 2009;182(1):55-63.
doi:10.1016/j.jneumeth.2009.05.020
16. Auer-GrumbachM, Bode H, Pieber TR, et al.
Mutations at Ser331 in the HSN type I gene SPTLC1
are associated with a distinct syndromic
phenotype. Eur J Med Genet. 2013;56(5):266-269.
doi:10.1016/j.ejmg.2013.02.002
17. Bejaoui K, Wu C, Scheffler MD, et al. SPTLC1 is
mutated in hereditary sensory neuropathy, type 1.
Nat Genet. 2001;27(3):261-262. doi:10.1038/85817
18. Dawkins JL, Hulme DJ, Brahmbhatt SB,
Auer-GrumbachM, Nicholson GA. Mutations in
SPTLC1, encoding serine palmitoyltransferase, long
chain base subunit-1, cause hereditary sensory
neuropathy type I. Nat Genet. 2001;27(3):309-312.
doi:10.1038/85879
19. Merrill AH Jr, Stokes TH, Momin A, et al.
Sphingolipidomics: a valuable tool for
understanding the roles of sphingolipids in biology
and disease. J Lipid Res. 2009;50(suppl):S97-S102.
doi:10.1194/jlr.R800073-JLR200
20. Penno A, Reilly MM, Houlden H, et al.
Hereditary sensory neuropathy type 1 is caused by
the accumulation of two neurotoxic sphingolipids.
J Biol Chem. 2010;285(15):11178-11187. doi:10.1074/
jbc.M109.092973
21. Wilson ER, Kugathasan U, Abramov AY, et al.
Hereditary sensory neuropathy type 1-associated
deoxysphingolipids cause neurotoxicity, acute
calcium handling abnormalities andmitochondrial
dysfunction in vitro. Neurobiol Dis. 2018;117:1-14.
doi:10.1016/j.nbd.2018.05.008
22. Nicholson GA. SPTLC1-related hereditary
sensory neuropathy. In: AdamMP, Ardinger HH,
Pagon RA, et al, eds. GeneReviews. University of
Washington; 2002.
23. Gantner ML, Eade K, Wallace M, et al.
Serine and lipid metabolism in macular disease
and peripheral neuropathy. N Engl J Med. 2019;381
(15):1422-1433. doi:10.1056/NEJMoa1815111
24. Sabourdy F, Astudillo L, Colacios C, et al.
Monogenic neurological disorders of sphingolipid
metabolism. Biochim Biophys Acta. 2015;1851(8):
1040-1051. doi:10.1016/j.bbalip.2015.01.010
25. Haughey NJ, Bandaru VV, BaeM, MattsonMP.
Roles for dysfunctional sphingolipid metabolism in
Alzheimer’s disease neuropathogenesis. Biochim
Biophys Acta. 2010;1801(8):878-886. doi:10.1016/j.
bbalip.2010.05.003
26. Mitsumoto H, Sliman RJ, Schafer IA, et al.
Motor neuron disease and adult hexosaminidase A
deficiency in two families: evidence for multisystem
degeneration. Ann Neurol. 1985;17(4):378-385.
doi:10.1002/ana.410170413
27. Cutler RG, PedersenWA, Camandola S,
Rothstein JD, MattsonMP. Evidence that
accumulation of ceramides and cholesterol esters
mediates oxidative stress-induced death of motor
neurons in amyotrophic lateral sclerosis. Ann Neurol.
2002;52(4):448-457. doi:10.1002/ana.10312
28. Garofalo K, Penno A, Schmidt BP, et al. Oral
L-serine supplementation reduces production of
neurotoxic deoxysphingolipids in mice and humans
with hereditary sensory autonomic neuropathy
type 1. J Clin Invest. 2011;121(12):4735-4745.
doi:10.1172/JCI57549
29. Fridman V, Suriyanarayanan S, Novak P, et al.
Randomized trial of L-serine in patients with
hereditary sensory and autonomic neuropathy
type 1.Neurology. 2019;92(4):e359-e370.
doi:10.1212/WNL.0000000000006811
30. Levine TD, Miller RG, BradleyWG, et al. Phase I
clinical trial of safety of L-serine for ALS patients.
Amyotroph Lateral Scler Frontotemporal Degener.
2017;18(1-2):107-111. doi:10.1080/21678421.2016.
1221971
31. Foley AR, Menezes MP, Pandraud A, et al.
Treatable childhood neuronopathy caused by
mutations in riboflavin transporter RFVT2. Brain.
2014;137(pt 1):44-56. doi:10.1093/brain/awt315
32. Boso F, Armirotti A, Taioli F, et al.
Deoxysphingolipids as candidate biomarkers for
a novel SPTLC1mutation associated with HSAN-I.
Neurol Genet. 2019;5(6):e365. doi:10.1212/NXG.
0000000000000365
Research Original Investigation Association of Variants in the SPTLC1 GeneWith Juvenile Amyotrophic Lateral Sclerosis
1248 JAMANeurology October 2021 Volume 78, Number 10 (Reprinted) jamaneurology.com
Downloaded From: https://jamanetwork.com/ on 11/29/2021
